BioPharma DiveOriginal article
UniQure tumbles with latest data for Huntington’s gene therapy
Data ReadoutnegativeAMT-130Negative
AI Analysis
Summary
UniQure's AMT-130 gene therapy for Huntington's disease showed weaker than expected durability at a four-year interim analysis, disappointing investors and raising questions about the strength of the clinical data supporting potential regulatory approval.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
Four-year check-in data showed weaker than expected durability results
Importance:7/10
Sentiment:
-0.80
gene therapyHuntington's diseaseclinical datadurabilityapproval pathway
Related Companies
Read the original article
Published by BioPharma Dive on September 29, 2026 3:36 PM